Trusted by:
Three recent papers highlight new promise, and expose nagging pitfalls, of one of the Alzheimer field's most widely used surrogate measures of disease progression. Developing validated biomarkers is critical for developing better diagnostics and treatments.
The web's foremost website on Alzheimer disease reports on the highlights from the 3rd annual Human Amyloid Imaging (HAI) conference held recently in Seattle, WA. Amyloid beta, a peptide that builds up abnormally in the brains of Alzheimer patients, can be studied by brain imaging. This landmark advance promises to yield new insights into how brain changes with aging and Alzheimer disease.
The Alzforum reports on the analyses of one-year data (preliminary and mostly unpublished) from the $64-million Alzheimer's Disease Neuroimaging Initiative (ADNI). Scientists reported, and debated, these much-anticipated findings at recent ADNI internal meeting and a few days later in an ADNI session at the 61st Annual Meeting of the American Academy of Neurology (AAN), both in Seattle.
Many cases of age-related neurodegenerative disease fall into the gray zone between big, defined diseases such as Alzheimer or Parkinson disease. They are often misdiagnosed, which is a problem because mixed disease is not only common, but also quite different in its course from pathologically 'pure' disease. But there's also excitement and opportunity.
While the occasional all-nighter to cram for exams or finish a grant proposal may seem like no big deal, losing sleep night after night could take its toll on brain health in later life, two new studies suggest. Read the full report on Alzforum.
Forget sun, sand, and surf—it was biomarker pools and a sea change in neurocognitive testing that rejuvenated attendees at the 8th Annual Symposium on Early Alzheimer's, held 12-13 March 2010, in Miami Beach, Florida. Our intrepid reporter Pat McCaffrey brings you a full meeting summary, complete with a slide deck that covers the majority of presentations.
Writing the latest pages of an anthropological mystery, scientists propose in this month’s Archives of Neurology that it is highly possible that Auguste Deter, the first identified Alzheimer disease patient, carried the N141I presenilin-2 mutation—the same one as in present-day U.S. families descended from German emigrants who settled near the river Volga in Russia.
A rigorous evaluation of the scientific literature reveals that the jury is still out when it comes to hormone replacement therapy and a woman’s risk for Alzheimer’s disease. The results are reported in the AlzRisk database.
Tau, the protein that tangles together in Alzheimer's, spreads from cell to cell in the mouse brain, perhaps explaining disease progression in humans, suggests a new study. "Alzheimer's disease seems to spread like an infection from brain cell to brain cell...." says The New York Times, but experts assure Alzforum that the disease is not contagious.
A small company with roots in Singapore and Scotland plans to test a relatively unknown compound in clinical trials for a type of dementia that strongly affects behavior.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right